Asset Details
Do you wish to reserve the book?
Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
Do you wish to request the book?
Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
2025
Overview
Alopecia has recently been reported as a potential emerging adverse effect associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are widely prescribed for weight loss. While gastrointestinal symptoms remain the most frequently documented adverse effects, an increasing number of reports describe hair loss events in patients treated with semaglutide, liraglutide, tirzepatide, and dulaglutide. This scoping review aimed to synthesize the available evidence regarding this potential association. A systematic literature search was conducted across PubMed, Scopus, Google Scholar, Cochrane, and the Latin American and Caribbean Literature on Health Sciences (LILACS) database through May 24, 2025. Nine studies met the inclusion criteria, comprising randomized clinical trials, cohort studies, and pharmacovigilance analyses. Most studies lacked dermatological diagnostic confirmation, and only one described the clinical pattern of alopecia, identifying telogen effluvium and androgenetic alopecia as the most frequent subtypes. The findings suggest that GLP-1RAs may alter the hair follicle cycle. More than 1,000 spontaneous cases have been reported in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Although a causal relationship cannot be confirmed, the recurrence of cases across diverse settings signals a potential safety concern that warrants clinical attention. Awareness of this possible effect may improve therapeutic adherence and prevent unnecessary diagnostic interventions. Further dermatological research is needed to better characterize the frequency, temporality, and underlying mechanisms of GLP-1RA-associated alopecia.
Publisher
Cureus Inc
Subject
